





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07H 21/00, C12Q 1/68, C07K 16/00</b>	A1	(11) International Publication Number: <b>WO 99/31115</b> (43) International Publication Date: <b>24 June 1999 (24.06.99)</b>
(21) International Application Number: <b>PCT/CA98/01149</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: <b>16 December 1998 (16.12.98)</b>		
(30) Priority Data: 2,218,443 16 December 1997 (16.12.97) CA 2,229,386 11 February 1998 (11.02.98) CA		
(71) Applicant ( <i>for all designated States except US</i> ): THE UNIVERSITY OF SASKATCHEWAN [CA/CA]; Kirk Hall, 117 Science Place, Saskatoon, Saskatchewan S7N 5C8 (CA).		
(72) Inventors; and		Published
(75) Inventors/Applicants ( <i>for US only</i> ): AICH, Palok [IN/CA]; University of Saskatchewan, Dept. of Biochemistry, Health Sciences Building, Room A3, Saskatoon, Saskatchewan S7N 5E5 (CA). LEE, Jeremy, S. [CA/CA]; University of Saskatchewan, Dept. of Biochemistry, Health Sciences Building, Room A3, Saskatoon, Saskatchewan S7N 5E5 (CA)..		<i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(74) Agents: KINGWELL, Brian, G. et al.; Smart & Biggar, Box 11560, Vancouver Centre, Suite 2200, 650 W. Georgia Street, Vancouver, British Columbia V6B 4N8 (CA).		

(54) Title: CONDUCTIVE METAL-CONTAINING NUCLEIC ACIDS

## (57) Abstract

The invention provides conductive polymers comprising metal-containing nucleic acid duplexes electrically coupled to an electron source. Methods for making conductive metal-containing nucleic acid duplexes are provided, comprising subjecting a nucleic acid duplex to basic conditions in the presence of a divalent metal cation. Methods of using conductive metal-containing nucleic acid duplexes are provided, including methods of genomic analysis, methods of molecular screening and immunological methods that produce antibodies to such molecules.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**CONDUCTIVE METAL-CONTAINING NUCLEIC ACIDS****FIELD OF THE INVENTION**

5        The invention is in the field of conductive polymers, particularly conductive nucleic acids, such as DNA, as well as methods for producing and using such compounds.

**BACKGROUND OF THE INVENTION**

10      Polymeric molecular conductors are known. For example, some naturally occurring proteins facilitate electron transfer in such fundamental biological processes as photosynthesis and respiration. Electron transfer in such systems is generally understood to occur as the result of quantum mechanical 'tunnelling' of electrons along pathways, molecular orbitals, that connect one atom to the next in the polymer.

15      It has been proposed that the stacked aromatic bases of DNA may act as a ' $\pi$ -way' for the transfer of electrons (Dandliker et al., 1997; Hall et al., 1996; Arkin et al., 1996). This proposal is based on a theory that the stacked arrangement of bases on complementary strands juxtaposes the shared electrons in the  $\pi$  orbitals of the aromatic nitrogen bases, facilitating 20 quantum mechanical tunnelling along the stack of base pairs. A number of experiments have supported the view that this effect exists, while other experiments have provided contrary evidence that the effect is limited or non-existent.

25      For example, experiments have been reported to demonstrate that photoinduced electron transfer may occur between two metallointercalators tethered at either end of a 15-base pair DNA duplex (Murphy et al., 1993). On the other hand, kinetic analysis of distance-dependent electron transfer in a DNA hairpin has been used to show that DNA is a poor conductor, only somewhat more effective than proteins as a conductor of electrons (Lewis et al., 1997; Taubes, 1997).

United States Patent Nos. 5,591,578; 5,705,348; 5,770,369; 5,780,234 and 5,824,473 issued to Meade *et al.* on, respectively, 7 January 1997, 6 January 1998, 23 June 1998, 14 July 1998 and 20 October 1998 (and incorporated herein by reference) disclose nucleic acids 5 that are covalently modified with electron transfer moieties along the nucleic acid backbone. Meade *et al.* teach that such modifications are necessary for nucleic acids to efficiently mediate electron transfer.

The theory of  $\pi$ -orbital-mediated conductance along a nucleic acid duplex suggests 10 that, as a precondition, such conductance requires a stable duplex with stacked base pairs. The effect on duplex stability of the binding of metal ions to nucleic acids, particularly DNA, has been studied extensively for nearly 40 years. In general, cations that bind primarily to the phosphate backbone will stabilize the duplex conformation, whereas those that bind to the bases will tend to denature the duplex. These effects are readily demonstrated with thermal 15 denaturation profiles ( $T_m$  measurements). Experiments of this sort show that most monovalent cations, such as  $\text{Na}^+$ , which tend to interact with the phosphate backbone, stabilize the duplex. This effect is reflected in the finding that there is approximately a 12 °C increase in  $T_m$  for each 10-fold increase in monovalent cation concentration (Marmur and Doty 1962). An exception to this general principle is  $\text{Ag}^+$ , which binds tightly to nitrogen 20 bases, destabilizes the duplex, and therefore decreases the duplex  $T_m$  (Guay and Beauchamp 1979). Similarly, multivalent ions, particularly polyamines, which interact with the phosphate backbone are very effective duplex stabilizers.

For divalent metal cations, a series can be written in increasing order of DNA 25 destabilization:  $\text{Mg}^{2+}$ ,  $\text{Co}^{2+}$ ,  $\text{Ni}^{2+}$ ,  $\text{Mn}^{2+}$ ,  $\text{Zn}^{2+}$ ,  $\text{Cd}^{2+}$ ,  $\text{Cu}^{2+}$  (Eichorn 1962; Eichorn and Shin 1968). At one end of the spectrum,  $\text{Mg}^{2+}$  increases the  $T_m$  at all concentrations; at the other end of the spectrum, sufficiently high concentrations of  $\text{Cu}^{2+}$  will lead to complete denaturation of the duplex at room temperature (Eichorn and Shin 1968). This series also

correlates with the ability of the divalent cations to bind to the bases (Hodgson 1977; Swaminathan and Sundaralingham 1979).

Cations are also involved in promoting several other structural transitions and 5 dismutations in nucleic acids. It has previously been reported that Zn<sup>2+</sup> and some other divalent metal ions bind to duplex DNA at pHs above 8 and cause a conformational change (Lee *et al.*, 1993). Preliminary characterization of the resulting structure incorporating zinc showed that it retained two antiparallel strands but that it was distinct from normal 'B' DNA: it did not bind ethidium bromide, it appeared to lose the imino protons of both A-T and G-C 10 base pairs upon addition of a stoichiometric amount of Zn<sup>2+</sup>, and it contained at least 5% fewer base pairs per turn than 'B' DNA.

## SUMMARY OF THE INVENTION

The invention provides an electrical conductor comprising an electron source 15 electrically coupled to a conductive metal-containing nucleic acid duplex (CM-CNA). An electron sink may also be electrically coupled to the CM-CNA. The CM-CNA comprises a first strand of nucleic acid and a second strand of nucleic acid. The first and the second nucleic acid strands include a plurality of nitrogen-containing aromatic bases covalently linked by a backbone (the backbone may be made up of phosphodiester bonds, as in DNA or 20 RNA, or alternative structures as discussed below). The nitrogen-containing aromatic bases of the first nucleic acid strand are joined by hydrogen bonding to the nitrogen-containing aromatic bases of the second nucleic acid strand. The nitrogen-containing bases on the first and the second nucleic acid strands form hydrogen-bonded base pairs in stacked arrangement along the length of the CM-CNA. At least some, and preferably each, of the hydrogen- 25 bonded base pairs comprises an interchelated divalent metal cation coordinated to a nitrogen atom in one of the aromatic nitrogen-containing bases.

The electron source electrically coupled to the CM-CNA may be an electron donor molecule capable of donating an electron to the conductive metal-containing nucleic acid

duplex. Similarly, the electron sink may be an electron acceptor molecule capable of accepting an electron from the CM-CNA. The electron donor molecule may be a fluorescent molecule, such as fluorescein. Similarly, the electron acceptor molecule may be a fluorescent molecule, such as rhodamine. It will be appreciated that some molecules may act both as electron  
5 donors and electron acceptors in various embodiments of the invention.

The CM-CNA may be made of deoxyribonucleic acid strands, which together produce metal-containing DNA ("M-DNA"). The nitrogen-containing aromatic bases in the nucleic acid may be the naturally occurring bases: adenine, thymine, guanine and cytosine.

10

In various embodiments, the divalent metal cation used to make CM-CNA may be  $Zn^{2+}$ ,  $Co^{2+}$ , or  $Ni^{2+}$ . Some divalent metal cations will not produce CM-CNA, and the present invention provides simple assays to determine whether a particular divalent metal cation will work to produce CM-CNA.

15

The divalent metal cations may be substituted for the imine protons of aromatic nitrogen-containing bases in the CM-CNA. In one embodiment, the divalent metal cations may be substituted for the N3 imine proton of thymine, or the imine protons of the N1 nitrogen atom of guanine.

20

The invention provides a method for making conductive metal-containing nucleic acid duplexes. A nucleic acid duplex is subjected to basic conditions in the presence of a divalent metal cation under conditions effective to form a conductive metal-containing nucleic acid duplex. Electron sources and sinks may be electrically coupled to the conductive metal-  
25 containing nucleic acid duplex, which may take the form of various embodiments discussed above.

The invention provides a method for detecting the formation of conductive metal-containing nucleic acid duplexes from first and second nucleic acid strands. The nucleic acid

strands are mixed under conditions which allow complementary stands to hybridize and subjected to basic conditions in the presence of a divalent metal cation under conditions effective to form a conductive metal-containing nucleic acid duplex if the first and second strands are complementary. An electron source is provided electrically coupled to the  
5 conductive metal-containing nucleic acid duplex. Conductance of electrons between the electron source and the conductive metal-containing nucleic acid duplex is then tested to determine whether a CM-CNA has formed. The CM-CNA may take the form of various embodiments discussed above.

10 CM-CNAs of the invention may be used to carry electrons. They may also be used to raise antibodies in an animal, producing antibodies to CM-CNA. This latter use takes advantage of the finding that in some embodiments and under certain conditions CM-CNAs may be nuclease resistant.

15 **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1: shows the release of protons on formation of M-DNA. Upon addition of NiCl<sub>2</sub>, protons are released and KOH was added (left axis) to maintain the pH at 8.5. After each addition 10 µl was removed to assess the formation of M-DNA by the ethidium fluorescence assay (Lee et al, 1993) (right axis). The experiment was performed in a 10 mL  
20 volume, with 1.1 mM in base pairs of calf thymus DNA. The DNA was dialyzed against water and sheared by passing through a 30 gauge needle five times. Arrow (a) indicates the putative point at which M-DNA formation began. This lag phase is proportional to the DNA concentration (data not shown) and may be due to the initial binding of the metal ion to the outside of the helix. Arrow (b) indicates the point at which 1.1 mM of H<sup>+</sup> had been released,  
25 beyond which precipitation of the M-DNA was observed.

Figure 2: shows a putative structure of M-DNA showing G-C and A-T base pairs. Putative hydrogen bonds and interactions between Zn<sup>2+</sup> and its coordinating groups are shown as dotted lines.

Figure 3: shows the fluorescence of fluorescein-labelled oligonucleotides during the formation of M-DNA (see Table 1 for the sequences of the 20-mer and 54-mer) (a) Effect of Zn<sup>2+</sup> on the 20-mer duplex. (i) F1-20-mer duplex without Zn<sup>2+</sup>; (ii) F1-20mer duplex with Zn<sup>2+</sup>; (iii) F1-20-mer-Rh duplex in the absence of Zn<sup>2+</sup>; (iv) F1-20mer-Rh duplex in the presence of Zn<sup>2+</sup>; (v) addition of EDTA after the formation of M-DNA. (b) Effect of Zn<sup>2+</sup> on the 54-mer duplex. (i) F1-54-mer-Rh with D-site binding protein (1ug/ml) (the site is located at the centre of the 54-mer duplex) in the presence of Zn<sup>2+</sup>; (ii) addition of proteinase K (50ug/ml) after 3,000 seconds; (iii) F1-54mer-Rh duplex wit Zn<sup>2+</sup>. The experiments were performed in 20mM NaBO<sub>3</sub> buffer, pH 9.0 at 20 °C with 10mM NaCl and 1 mM Zn<sup>2+</sup> as appropriate. Fluorescence intensities are normalized with respect to the fluorescence intensity of the F1-20-mer-duplex either in the absence or presence of Zn<sup>2+</sup>.

Figure 4: shows the nuclease resistance of M-DNA. The amount of duplex DNA remaining as a function of time was assessed by the ethidium fluorescence assay (under conditions where M-DNA rapidly reverts to B-DNA, pH 8, 0.1 mM EDTA, so that ethidium can bind the DNA). The digestion was performed at 37°C in 10mM Tris-HCl, pH 7.4, 5 mM MgCl<sub>2</sub>, 1 mM NiCl<sub>2</sub>, 1 mg/ml gelatin, and 0.2 g/ml DNase I. The Ni<sup>2+</sup> form of M-DNA was preformed for the assay at pH 9 before adding it to the digestion buffer; B-DNA was added directly to the digestion buffer. The graph shows that the M-DNA is resistant to nuclease digestion while B-DNA is digested in about 10 minutes. The results also demonstrate that the Ni<sup>2+</sup> form of M-DNA is stable at physiological pH, a characteristic which facilitates the use of Ni<sup>2+</sup>-M-DNA to mediate physiological responses *in vivo*, such as DNA immunization (in which the DNA 'vaccine' expresses an antigenic protein) or antisense applications (in which injected M-DNA inhibits the expression of a complementary gene).

Figure 5: shows that M-DNA is immunogenic. Balb/C mice were immunized interperitoneally three times at ten day intervals with 10 µg of nickel-containing M-DNA, with and without methylated bovine serum albumin (Me-BSA). The first injection was with

complete Freunds adjuvant and subsequent injections were with incomplete Freunds adjuvant. Three days after the final injection, blood was obtained by tail bleeding and the serum was tested for the present of antiM-DNA antibodies using nickel M-DNA coated polyvinylchloride plates in a SPIRA assay, using methods known in the art (Braun and Lee, 5 1988).

Figure 6: is a schematic illustration showing as aspect of the invention that comprises a method of sequence analysis, in which one sequence that is susceptible to cutting by a restriction endonuclease may be distinguished from another sequence that is not susceptible 10 on the basis of the presence or absence of conductance in an M-DNA duplex formed between an electron donor, shown as "F" for fluorescein in the figure, and an electron acceptor, shown as "R" for rhodamine in the figure.

Figure 7: is a schematic illustration showing a nucleic acid coupled to electrode 10 15 and subjected to conditions suitable to form M-DNA, while measurements are taken of the conductance of the CM-CNA by cyclic voltammetry, both in the absence and presence of a DNA-binding drug.

#### **DETAILED DESCRIPTION OF THE INVENTION**

20 The invention provides a CM-CNA duplex comprising an electron source electrically coupled to a nucleic acid duplex in which at least some of the stacked, aromatic nitrogen-containing base pairs chelate divalent metal cations. In such an embodiment, the metal-containing nucleic acid duplex acts as an electron acceptor, receiving electrons from the electron donor. In one embodiment of this aspect of the invention, the imine protons of a 25 DNA duplex may be replaced by  $Zn^{2+}$ ,  $Co^{2+}$  or  $Ni^{2+}$ . The metal-containing DNA duplex may, for example be electronically coupled to molecular electron donors or electron sinks, such as fluorescein or rhodamine respectively, by covalent attachment.

In one aspect, the present invention provides a method for converting a nucleic acid duplex to CM-CNA. A nucleic acid duplex is treated with sufficient base in the presence of an adequate concentration of an appropriate divalent metal ion to result in the chelation of the divalent metal ion by the aromatic nitrogen bases of the nucleic acid. Such treatment is 5 carried out for a sufficient period of time to produce a modified duplex comprising the divalent metal cation coordinated to nitrogen atoms in the aromatic nitrogen-containing bases of base pairs.

In one embodiment, conditions for converting DNA, such as a B-DNA, to M-DNA 10 comprise subjecting the DNA to a solution at pH 8.5 or greater, with approximate concentrations of divalent metal ions as follows: 0.1 mM Zn<sup>2+</sup> or 0.2mM Co<sup>2+</sup> or 0.2mM Ni<sup>2+</sup>. The conditions necessary to form M-DNA will vary depending on the metal ion or ions used and the nature of the nucleic acid. Those skilled in this art will appreciate that routine experiments may be carried out to determine appropriate conditions, varying parameters such 15 as pH, nucleic acid concentration, metal ion concentration and the ratio of the metal ion concentration to the nucleic acid concentration. In some embodiments, a pH equal to or greater than 8, or greater than 8.5, may be required, and a suitable nucleic acid to metal ion ratio may be about 1:1.5 to about 1:2.0.

20 The MC-CNA may be electrically coupled to an electron source and an electron sink. For example, molecular electron donors and acceptors may act respectively as electron sources and electron sinks. In alternative embodiments, the electron donors and acceptors may be in solution, interacting transiently with the CM-CNA, or they may be in the form of a solid support, such as an electrode.

25

Solid phase supports to which the CM-CNA is attached may serve as electron sources, sinks or both. For example, immobilized arrays of CM-CNA may be prepared in accordance with the teaching of United States Patent No. 5,556,752, issued 17 September 1996 to Lockhart et al. (the "752 Patent", incorporated herein by reference). Such immobilized arrays

may then be used, as described therein and modified as necessary, to detect hybridization. In accordance with the present invention, the step of hybridizing the target nucleic acid to the immobilized probe may be followed, or accompanied, by the step of converting resulting duplexes to MC-CNA under basic conditions in the presence of a divalent metal cation, as 5 described herein. Electron donors and acceptors may be provided in such a system, as described in the '752 Patent, so that the conductivity of the resulting MC-CNA duplex is detectable at the surface of the immobilization substrate, as is also described in the '752 Patent. It will be appreciated that such a system involves the use of MC-CNA as a conductor, which is one aspect of the present invention.

10

The formation of CM-CNA may be used to assay a variety of nucleic acid interactions. For example, the amplification of a target sequence using the polymerase chain reaction (PCR) may be assayed using methods of the present invention. In one aspect of such an assay, one PCR primer is provided with an electron donor moiety and the other PCR 15 primer is provided with an electron acceptor moiety. In accordance with this aspect of the present invention, following PCR amplification cycles, the reaction mixture may be subjected to basic conditions in the presence of a divalent metal cation to promote the formation of CM-CNA. If the PCR amplification has been successful, CM-CNA will have formed and will be detectable as disclosed herein as a result of characteristic conductance between the 20 electron donor and the electron acceptor. Unsuccessful amplification will leave the electron transfer moieties on the primers electrically uncoupled. In some embodiments, this approach may have the advantage of allowing detection of amplification without the need to separate the PCR primers from the PCR reaction mixture following amplification cycles. In accordance with this aspect of the invention, a kit may be provided comprising PCR primers 25 having electron donors and electron acceptors, together with instructions for subjecting an amplification reaction mixture to basic conditions in the presence of a divalent metal cation to form CM-CNA. Such kits with appropriate instructions may also be provided for the other aspects of the invention disclosed herein

Ligation of nucleic acids may also be assayed using methods of the present invention, wherein successful ligation is detectable by the formation of CM-CNA. In such a system, one of the nucleic acid duplexes to be ligated may be provided with an electron donor moiety, while the other nucleic acid duplex to be ligated is provided with an electron acceptor moiety.

5 Ligation and subsequent formation of MC-CNA electrically couples the electron transfer moieties, producing a signal under appropriate conditions that is indicative of successful ligation. A kit may be provided for such a reaction, comprising an electron donor label and an electron acceptor label, together with instructions for coupling the electron donor and electron acceptor to nucleic acids that are to be ligated, and subjecting the ligation reaction mixture to  
10 basic conditions in the presence of a divalent metal cation to form CM-CNA.

In one embodiment of the invention, conditions are adapted to convert a B-DNA duplex to M-DNA. In one aspect of the invention, M-DNA is formed at pHs at or above 8 in the presence of sufficient amounts (preferably, in some embodiments, about 0.1 mM,  
15 provided the nucleic acid concentration is less than about 0.1 mM) of Zn<sup>2+</sup>, Ni<sup>2+</sup> or Co<sup>2+</sup>. In such an embodiment, Mg<sup>2+</sup> or Ca<sup>2+</sup> may not serve to produce M-DNA (Lee *et al.*, 1993). A wide variety of bacterial and synthetic DNAs may dismutate to M-DNA under these conditions. In some embodiments, the process of M-DNA formation may be reversible by lowering the pH and/or addition of EDTA. In some embodiments, Ni-M-DNA requires  
20 EDTA to be converted to 'B' DNA at pHs greater than about 7. In some embodiments, poly[d(AT)] may not be convertible to M-DNA under such conditions. Unlike B-DNA, ethidium will not bind to some embodiments of M-DNA, and this property forms the basis of a rapid and sensitive "ethidium fluorescence assay" that may be used to monitor M-DNA formation (Lee *et al.*, 1993).

25

M-DNA may be readily interconverted with B-DNA; therefore, useful techniques for manipulation of DNA such as cutting and splicing, and for the self-assembly of a variety of structures (such as two and three-way junctions) may be used with M-DNA forming sequences, as are well known in the art (Lilley and Clegg, 1993; Seeman and Kallenbach,

1994). In addition, the binding of sequence-specific proteins to CM-CNAs may be manipulated in some embodiments to interfere with conductance of the M-DNA so as to mimic electric switches and resistors.

5 One aspect of the invention provides methods for detecting particular sequences in genomic analysis, such as methods for detecting particular mutations. In one such aspect of the invention, as shown in Fig. 6, the nucleic acid to be analysed (shown as wild type or mutant) is amplified by PCR using primers, one of the primers being labelled with an electron donor and the other being labeled with an electron acceptor, such as fluorescein (shown as  
10 "F") and rhodamine (shown as "R") respectively. Following amplification, the nucleic acid is treated with a restriction enzyme which may or may not cut the amplified sequence, depending upon the nature of the amplified sequence. For example, the restriction enzyme may only cut one allele of a gene, leaving other alleles or non-wild type sequences uncleaved (as shown in Fig. 6, where X and Y represent a mutant base pair). Following treatment with  
15 the restriction enzyme the amplified sequence may be subjected to conditions suitable for the formation of a CM-CNA, for example amplified DNA duplexes may be converted to M-DNA. The fluorescence of the sample may then be measured. If the amplified duplex spans the region between the primers, as in the mutant gene of Figure 6, then the fluorescence of the amplified nucleic acid will be quenched by electron transfer along the CM-CNA. If, on the  
20 other hand, as in the wild type gene of Figure 6, the amplified duplex has been cut by the restriction enzyme, the fluorescence of the electron donor will not be quenched. A sample in which half of the sequences formed CM-CNA and half did not, such as may be the case in an analysis of a sample from an individual with an autosomal recessive mutation, the degree of fluorescence may be intermediate. Sequence analysis in accordance with this aspect of the  
25 invention may be carried out in an automated fashion. For example, in one aspect this approach may simultaneously use multiple reaction wells to carry out such reactions, each well containing different reagents, such as different primers or different restriction enzymes, to yield an abundance of information about a particular sample in a relatively short time without the necessity of electrophoresis or other more time-consuming steps.

In an alternative aspect, the invention provides a sensor for monitoring the presence of nucleic acid binding moieties in a sample. In one embodiment of this aspect of the invention, as shown in Figure 7, a nucleic acid duplex capable of forming a CM-CNA is attached between an electron sink and an electron donor, such as ferrocene, the nucleic acid is exposed to a sample under conditions that favour the formation of a CM-CNA duplex, the binding of a moiety to the nucleic acid is detected by a change in the conductance of the nucleic acid. For example, DNA binding molecules may convert M-DNA back to B-DNA under such conditions, and thereby prevent or reduce the CM-CNA mediated quenching of a fluorescent electron donor that is coupled to the nucleic acid. In one embodiment, the nucleic acid may be coupled to an electrode (for example as described in Braun *et al.*, Nature, 391: 775-778, 1998, incorporated herein by reference), such as gold electrode 10 of Figure 7, and the electrode may then be used to measure the conductance of the CM-CNA while the electrode is exposed to a sample. In some embodiments, for example, such conductance measurements may utilize cyclic voltammetry (shown as CV in Figure 7). Such, assays involving the detection of variations in the conductance of a CM-CNA may be used in various embodiments of the invention to detect interactions between nucleic acids and a wide variety of other moieties, such as small molecules, triplex-forming oligonucleotides and DNA-binding proteins.

In some embodiments, the conductance of MC-CNAs may be enhanced by modification of the nucleic acid with electron transfer moieties, such as is taught in the following U.S. Patent Nos. 5,591,578; 5,705,348; 5,770,369; 5,780,234 and 5,824,473 issued to Meade *et al.* on respectively 7 January 1997, 6 January 1998, 23 June 1998, 14 July 1998 and 20 October 1998 (and incorporated herein by reference).

25

In the context of the present invention, 'conductive' means capable of conducting electrons. An electron source in accordance with the present invention may be any compound or substance capable of providing electrons, such as an atomic or molecular conductor. Similarly, an electron sink (or acceptor) may be any compound or composition capable of

accepting electrons. A nucleic acid duplex comprises hybridized strands of nucleic acid molecules. A strand of nucleic acid comprises at least two nucleotides covalently linked by a backbone. The backbone may be made up of polymeric phosphodiester bonds, as in DNA or RNA. Alternatively, other backbone structures may be effective to appropriately align the 5 aromatic nitrogen-containing bases in a stacked arrangement capable of chelating metal ions and conducting electrons. For example, phosphoramido, phosphorothioate, phosphorodithioate, O-methylphosphoroamidite or peptide nucleic acid linkages may be effective to form such a backbone. Similarly, other components of the backbone may vary in accordance with the invention, encompassing deoxyribose moieties, ribose moieties, or 10 combinations thereof. If RNA is used, those skilled in this art will appreciate that conditions must be adapted to account for the fact that RNA is labile in basic solution, so that conversion of RNA to CM-CNA may require modified reaction conditions which avoid hydrolysis of the RNA. In one aspect of the invention, the nitrogen-containing aromatic bases are preferably those that occur in native DNA and RNA: adenine, thymine, cytosine guanine or uracil.

15 However, those skilled in this art will understand that alternative nitrogen-containing aromatic bases may be utilized, preferably they are capable of interchelating a divalent metal ion, coordinated to a nitrogen atom in the aromatic nitrogen-containing base and stacking, to produce a conductive metal-containing nucleic acid duplex. In accordance with these variations in the structure of the molecules of the invention, alternative divalent metal ions 20 may be utilized, again depending upon the ability of such ions to participate with the other substituents of the molecules of the invention in the formation of a conductive metal-containing nucleic acid duplex. The present application sets out assays for the creation of such a duplex, so that others may routinely identify functional substitutions and variations in the structure of the molecules of the invention. Accordingly, although various embodiments 25 of the invention are exemplified herein, other adaptations and modifications may be made within the scope of the invention. The following examples are merely illustrative of alternative embodiments of the invention and are not comprehensive nor limiting in their scope.

**EXAMPLE 1****Conductance of MC-CNA**

The conductance of MC-CNA was investigated by preparing duplexes of 20 base pairs of DNA with fluorescein (the electron donor) and rhodamine (the electron acceptor) at 5 opposite ends of the duplex. Methods for such attachment are disclosed in Kessler, 1995, and Haugland, referenced below. Fluorescein and rhodamine fluoresce at different wavelengths, so that it is possible to distinguish fluorescence of the electron donor from fluorescence of the electron acceptor. Under conditions which favour B-DNA (pH less than about 8.0 in the presence of EDTA) the fluorescence of the fluorescein electron donor is partially quenched 10 and the fluorescence of the rhodamine electron acceptor is partially enhanced. This appears to be an example of through space energy transfer (Forster resonance energy transfer or FRET) which has been well-documented in a number of different laboratories (Cheung, H.C. 1991 and Clegg, R.M., 1992). FRET quenching is understood to be due to dipole-dipole interactions along a molecule (not electron conductance) and is highly distance dependent 15 (the effect decreasing with interatom distance in sixth order relationship:  $1/r^6$ ); the value of 25% quenching measured for the 20 base pair duplex is in accordance with the expected FRET behaviour for this length of helix (Clegg, 1992). As shown in Figure 3a, the fluorescence intensity is relatively stable at pH 9 although at long times there is some loss due to photobleaching.

20

On addition of  $Zn^{2+}$  (1 mM) to the DNA (pH 9), the fluorescence is quenched up to 95% over a period of 1 hr. This rate of increasing quenching mirrors the known rate of formation of M-DNA under these conditions (Lee *et al.*, 1993). Upon reformation of B-DNA by addition of an excess of EDTA (2 mM) after 4,000 sec., the quenching is rapidly reversed.

25 These results are summarized in Table 1.

As a control, the 20-mer duplex (without metal ions) with a fluorescein label shows only a small decrease in intensity due to photobleaching, similar to the effect noted above with respect to ordinary B-DNA (Figure 3a). Similarly a mixture of two duplexes, one

labelled with fluorescein and the other labelled with rhodamine, show minimal quenching either as B-DNA or M-DNA (see Table 1).

To measure the fluorescence life time of the fluorescein when it is attached to the 20-  
5 mer oligonucleotide having fluorescein at one end and rhodamine at the other end, the  
fluorescein is irradiated with a picosecond pulse of laser light and the fluorescence decay of  
the excited fluorescein is then followed for several nanoseconds. Normally (as is the case  
with B-DNA) the  $t_{1/2}$  for decay is about 3 nanoseconds. Upon conversion to the  $Zn^{2+}$  form of  
M-DNA as described above, the  $t_{1/2}$  drops to about 0.3 nanoseconds. This extremely fast  
10 decay is consistent with electron conductivity by the M-DNA helix.

Electron transfer in the  $Zn^{2+}$  isomer of M-DNA was investigated in a longer helix of  
54 base pairs (this 54mer has an estimated length of over 150Å). This 54mer also contained  
the recognition site for the D-site binding protein (Roesler et al., 1992) in the middle of the  
15 sequence. As shown in Figure 3b, there is no quenching in the absence of metal ions in the  
54mer, this may be because the fluorophores are well separated so that there is no FRET.  
However, upon addition of  $Zn^{2+}$  under appropriate conditions to form M-DNA (1mM  $Zn^{2+}$ ,  
pH 9), the fluorescent intensity rapidly drops to 25% of the initial value, demonstrating  
efficient conductance over the length of the 54mer.

In the presence of the D-site binding protein, under conditions appropriate to form M-  
DNA, the fluorescence intensity of the 54mer only drops slowly. However, as judged from  
the ethidium fluorescence assay (Lee et al., 1993), the majority of the 54mer DNA is in the  
form of M-DNA (which does not bind ethidium). This demonstrates that the D-site DNA-  
25 binding protein is interrupting the flow of electrons along the 54mer M-DNA duplex. As a  
control, the D-site binding protein has no effect on the quenching of the 20-mer (which as no  
D-site binding sequence, see Table 1). On addition of protease at 3000 seconds to the D-site  
binding protein:54mer M-DNA complex, the protein is cleaved and the fluorescence intensity  
begins to drop, eventually reaching the minimum value of 25% of the initial fluorescence

value. This experiment is a simple example of a bioreactive electronic switch comprising CM-CNA and a DNA-binding protein capable of disrupting the conductive duplex. Such a switch is also analogous to an electronic memory element, having two interchangeable states, conductive and non-conductive.

5

**Table 1. Normalized Fluorescence of the Fluorescein-labelled oligonucleotides**

	Oligonucleotide	Treatment	Fluorescence
10	Fl-20-mer duplex	none	1
	Fl-20-mer duplex	+Zn <sup>2+</sup>	0.98
	Fl-20-mer duplex	+Zn <sup>2+</sup> at pH 8.0	0.92
	Fl-20-mer single strand	none	0.87
15	Fl-20-mer duplex + Rh-20-mer duplex	none	0.97
	Fl-20-mer-Rh duplex	none	0.73
	Fl-20-mer-Rh duplex	+Zn <sup>2+</sup>	0.05
	Fl-20-mer-Rh duplex	+Zn <sup>2+</sup> + EDTA	0.87
	Fl-20-mer-Rh duplex	+Zn <sup>2+</sup> at pH 8.0	0.92
20	Fl-20-mer-Rh duplex	+Co <sup>2+</sup>	0.05
	Fl-20-mer-Rh duplex	+Co <sup>2+</sup> +EDTA	0.7
	Fl-20-mer-Rh duplex	+Ni <sup>2+</sup>	0.06
	Fl-20-mer-Rh duplex	+Ni <sup>2+</sup> +EDTA	0.7
	Fl-20-mer-Rh duplex	+Mg <sup>2+</sup>	0.83
25	Fl-20-mer-Rh duplex	+D-site binding protein + Zn <sup>2+</sup>	0.06
	Fl-54-mer-Rh	+D-site binding protein + Zn <sup>2+</sup>	1
	Fl-54-mer-Rh	+Zn <sup>2+</sup>	0.21

Conversion to M-DNA was performed in 20mM NaBO<sub>3</sub> buffer, pH 9.0. Fluorescence assays were carried out in 20 mM Tris pH 8.0. Other conditions were as follows: 10mM NaCl at 20 °C and 1 mM Zn<sup>2+</sup> or 0.2 mM Co<sup>2+</sup> or 0.2 mM Ni<sup>2+</sup> or 2 mM EDTA as appropriate. Excitation was at 490 nm with emission measured at 520 nm. Fluorescence intensities are normalized with respect to the fluorescence intensity of the Fl-20-mer-duplex either in the absence or presence of Zn<sup>2+</sup> and were measured after 3,000 sec.

35

Sequences and nomenclature: The oligonucleotides were labelled 5' with fluorescein (Fl) or rhodamine (Rh) using standard attachment methods and constructs, for example as used in DNA sequencing. The fluorescein 20-mer was as follows: SEQ ID 1: F1-5'-d(GTC

ACG ATG GCC CAG TAG TT). The rhodamine 20-mer was as follows: SEQ ID 2: Rh-5'-d(AAC TAC TGG GCC ATC GTG AC). The same unlabelled sequence was used to produce the F1-20-mer-duplex. The F1-54-mer was as follows: SEQ ID 3: F1-5'-d(GCT ATG ATC CAA AGG CCG GCC CCT TAC GTC AGA GGC GAG CCT CCA GGT CCA GCT) (The 5 D-site is underlined). The Rh-54mer was as follows: SEQ ID 4: Rh-5'-d(AGC TGG ACC TGG AGG CTC GCC TCT GAC GTA AGG GGC CGG CCT TTG GAT CAT AGC). The same unlabelled sequence was used to produce the F1-54-mer duplex.

This Example demonstrates a method for converting a nucleic acid duplex to a 10 conductive metal-containing nucleic acid duplex, in this case M-DNA. The excited electron on the fluorescein is rapidly transmitted down the M-DNA helix to the rhodamine; demonstrating rapid and efficient electron transfer along the M-DNA. The Co<sup>2+</sup> and Ni<sup>2+</sup> isomers of M-DNA show quenching of the fluorescein by up to 95% even in the absence of the rhodamine acceptor (Table 1). This indicates that the M-DNA can itself act as an electron 15 acceptor.

## EXAMPLE 2

### Physical Properties of M-DNA

The mobility of linear or covalently closed circular forms of M-DNA in agarose gels 20 is only slightly less than that of B-DNA (indicating that treatment in accordance with the invention to produce M-DNA need not cause condensation or aggregation of the DNA). NMR studies show that the imino protons of T (pKa 9.9) and G (pKa 9.4) may not be present in M-DNA, illustrating that the imine protons may be replaced by the divalent metal cation in M-DNA. The release of protons during the formation of M-DNA may be indicative of this 25 phenomenon. As shown in Figure 1, M-DNA begins to form at about 0.7 mM NiCl<sub>2</sub> (as judged from the ethidium fluorescence assay); there is a concomitant release of protons so that KOH may be added to maintain the pH at 8.5. At 1.8 mM NiCl<sub>2</sub>, M-DNA formation is virtually complete and the complex starts to precipitate. This suggests that one proton is released per Ni<sup>2+</sup> atom per base pair during the formation of M-DNA. The Zn<sup>2+</sup> and Co<sup>2+</sup>

isomers of M-DNA also release protons during formation, and precipitation of the complex may occur at a lower concentration of divalent metal ion than with Ni<sup>2+</sup>. These results are consistent with the metal ion being coordinated to the N3 position of T and N1 of G in the base pairs.

5

Based on these observations, a putative structure for M-DNA can be modelled as shown in Figure 2. This model reflects experimental results relating to one aspect of the present invention, and does not limit the invention to any such putative structure. The model may nevertheless be helpful to others in practising routine variations of the invention. In this 10 putative structure, the A-T and G-C base pairs are isomorphous, which is a common feature of stable helical nucleic acid structures (Paleck, 1991). Compared to a Watson-Crick base pair, insertion of the metal ion with an imino N-metal bond of 2Å (Swaminathan and Sundralingham, 1979; DeMeester, 1973; McGall and Taylor, 1973) requires a 20°-30° rotation of the bases which opens up the minor groove. One hydrogen bond is retained in both 15 base pairs, which may facilitate rapid reformation of normal B-DNA without denaturation of the helix on removal of the metal ion. The coordination geometry of the metal ion may be distorted square planar with the solvent providing the fourth ligand in some embodiments. The UV-Vis spectrum of the Co<sup>2+</sup> and Ni<sup>2+</sup> isomers of M-DNA have peaks in the visible with ε of 20 and 60 mol<sup>-1</sup> cm<sup>-1</sup> respectively; an observation which is consistent with this 20 geometry (Lever, 1988). In this putative model of an M-DNA duplex, the metal ion is buried within the helix and d-π bonding may occur with the aromatic bases above and below the metal ion. The putative model helix could be considered as a distorted member of the B-type helix family in agreement with the unremarkable CD spectrum (Lee et al, 1993.). On average the model metal-metal distance is 4Å.

25

### EXAMPLE 3

#### M-DNA Is Nuclease Resistant

The nuclease resistance of M-DNA was established by assaying the amount of duplex M-DNA remaining as a function of time in the presence of DNase I, as shown in Figure 4.

The amount of DNA was assessed by the ethidium fluorescence assay (under conditions where M-DNA rapidly reverts to B-DNA, *i.e.* pH 8 in the presence of EDTA, so that ethidium can bind the DNA for the purpose of the assay). The digestion was performed at 37°C in 10mM Tris-HCl, pH 7.4, 5 mM MgCl<sub>2</sub>, 1 mM NiCl<sub>2</sub>, 1 mg/ml gelatin, and 0.2 g/ml 5 DNase I. The Ni<sup>2+</sup> form of M-DNA was preformed for the assay at pH 9, before adding it to the digestion buffer; B-DNA was added directly to the digestion buffer. The graph shows that the M-DNA is resistant to nuclease digestion while B-DNA is digested in about 10 minutes. The results also demonstrate that the Ni<sup>2+</sup> form of M-DNA is stable at physiological pH, a characteristic which may facilitate the use of Ni-M-DNA to mediate physiological responses 10 in vivo, such as DNA immunization (in which the DNA vaccine expresses an antigenic protein) or antisense applications (in which injected M-DNA inhibits the expression of a gene).

#### EXAMPLE 4

15 **M-DNA Is Immunogenic**

B-DNA is generally not immunogenic. However, synthetic or modified nucleic acids that are nuclease resistant may be capable of producing an antibody response under certain conditions (Braun and Lee, 1988).

20 To test the immunogenicity of M-DNA, Balb/C mice were immunized interperitoneally three times at ten day intervals with 10 µg of nickel-containing M-DNA, with and without methylated bovine serum albumin (Me-BSA). The first injection was with complete Freunds adjuvant and subsequent injections were with incomplete Freunds adjuvant. Three days after the final injection, blood was obtained by tail bleeding and the 25 serum was tested for the present of antiM-DNA antibodies using nickel M-DNA coated polyvinylchloride plates in a SPIRA assay, using methods known in the art (Braun and Lee, 1988).

The results, shown in Figure 5, demonstrate that the mice immunized with M-DNA (with and without Me-BSA) show antibody titres to M-DNA up to about 1:1000 dilution. The control sera from an unimmunized mouse contains no antibodies to M-DNA. The ability of M-DNA to elicit an immune response is consistent with the finding that M-DNA may be 5 nuclease resistant (see Braun and Lee, 1988). Accordingly, in some embodiments, M-DNA may be useful for immunizing a host, for example in methods as disclosed in U.S. Patent Nos. 5,679,647; 5,804,566 or 5,830,877 issued to Carson et al. on, respectively 21 October 1997, 8 September 1998 and 3 November 1998 (and incorporated herein by reference).

10

## REFERENCES

1. Dandliker, P. J., Holmlin, R. E. & Barton, J. K. Science 275,1465-1468 (1997) .
2. Hall, D. B., Holmlin, R. E. & Barton, J. K. Nature 382, 731-735 (1996).
3. Arkin, M. R., Stemp, E. D. A., Holmlin, R. E., Barton, J. K., Hormann, A., Olson, E. J. C. & Barbara, P. F. Science 273,475-479 (1996).
- 15 4. Murphy, C. J., Arkin, M. R., Jenkins, Y., Ghatlia, N. D., Bossmann, S. H., Turro, N.J. & Barton, J. K. Science 262,1025-1029 (1993).
5. Lewis, F. D., Wu, T., Zhang, Y., Letsinger, R. L., Greenfield, S. R., & Wasilewski, M. R.Science 277,673-676 (1997) .
6. Taubes, G. Science 275,1420-1421 (1997).
- 20 7. Lee, J. S., Latimer, L. J. P. & Reid, R. S. Biochem. Cell Biol. 71, 162-168 (1993).
8. Palecek, E. CRC Crit. Rev. Biochem. Mol. Biol. 26,151-226 (1991).
9. Yagil, G. CRC Crit. Rev. Biochem. Mol. Biol. 26, 475-559 (1991).
10. Swaminathan, V. & Sundralingham, M. CRC Crit. Rev. Biochem. Mol. Biol. 14, 245-336 (1979).
- 25 11. DeMeester, P., Goodgame, D. M. L., Skapski, A. C. & Warnke, Z. Biochem. Biophys. Acta 324,301-303 (1973).
12. McGall, M. J. & Taylor, M. R.Biochem. Biophys. Acta 390,137-139 (1973).
13. Lever, A. B. P. "Inorganic Electronic Spectroscopy" (Elsevier, Amsterdam) (1988).

14. Cheung, H. C. in "Topics in Fluorescence Spectroscopy" pp 128-171, ed. Lakowicz, J. R. (Plenum, New York) (1991).
15. Clegg, R. M. Methods in Enzymology 211,353-371 (1992).
16. Roesler, W. J., McFie, P. J. & Dauvin, C. J. Biol. Chem. 267, 21235-21243 (1992).
- 5 17. Lilley, D. M. J. & Clegg, R. M. Ann. Rev. Biophys. Biomol. Str. 22, 299-328 (1993).
18. Seeman, N. C. & Kallenbach, N. R. Ann. Rev. Biophys. Biomol. Str. 23, 53-86 (1994).
19. Brunger, A. I. X-PLOR Manual, version 3.1 (rare University Press New Haven USA (1993).
20. Braun, R.P. and Lee, J.S. J. Immunol. v.141, 2084-2089 (1988).
- 10 21. Kessler, C. in *Nonisotopic Probing, Blotting and Sequencing*, L.J. Kricka, Ed., Academic Press (1995) pp. 3-40.
22. Haugland, R.P. *Handbook of Fluorescent Probes and Research Chemicals*, 6th Ed., p.157.

**What is claimed is:**

1. An electrical conductor comprising an electron source electrically coupled to a conductive metal-containing nucleic acid duplex, the conductive metal-containing nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, the first and the second nucleic acid strands comprising a plurality of nitrogen-containing aromatic bases covalently linked by a backbone, the nitrogen-containing aromatic bases of the first nucleic acid strand being joined by hydrogen bonding to the nitrogen-containing aromatic bases of the second nucleic acid strand, the nitrogen-containing aromatic bases on the first and the second nucleic acid strands forming hydrogen-bonded base pairs in stacked arrangement along the length of the conductive metal-containing nucleic acid duplex, the hydrogen-bonded base pairs comprising an interchelated divalent metal cation coordinated to a nitrogen atom in one of the aromatic nitrogen-containing aromatic bases.  
10
- 15 2. The electrical conductor of claim 1 further comprising an electron sink electrically coupled to the conductive metal-containing nucleic acid duplex.
3. The electrical conductor of claim 1 or 2 wherein the electron source is an electron donor molecule capable of donating an electron to the conductive metal-containing  
20 nucleic acid duplex.
4. The electrical conductor of claim 2 or 3 wherein the electron sink is an electron acceptor molecule capable of accepting an electron from the conductive metal-containing nucleic acid duplex.  
25
5. The electrical conductor of claim 3 wherein the electron donor molecule is a fluorescent molecule.

6. The electrical conductor of claim 4 wherein the electron acceptor molecule is a fluorescent molecule.
7. The electrical conductor of claim 5 wherein the electron donor molecule is fluorescein.
8. The electrical conductor of claim 6 wherein the electron acceptor molecule is rhodamine.
- 10 9. The electrical conductor of any one of claims 1 through 8 wherein the first and the second nucleic acid strands are deoxyribonucleic acid and the nitrogen-containing aromatic bases are selected from the group consisting of adenine, thymine, guanine and cytosine.
- 15 10. The electrical conductor of any one of claims 1 through 9 wherein the divalent metal cation is selected from the group consisting of  $Zn^{2+}$ ,  $Co^{2+}$ , and  $Ni^{2+}$ .
11. The electrical conductor of any one of claims 1 through 10 wherein the divalent metal cations are substituted for imine protons of the nitrogen-containing aromatic bases, and the nitrogen-containing aromatic bases are selected from the group consisting of thymine and guanosine.
- 20 12. The electrical conductor of any one of claims 1 through 11 wherein at least one of the aromatic nitrogen-containing aromatic bases is thymine, having an N3 nitrogen atom, and the divalent metal cation is coordinated by the N3 nitrogen atom.
- 25 13. The electrical conductor of any one of claims 1 through 12 wherein at least one of the aromatic nitrogen-containing aromatic bases is guanine, having an N1 nitrogen atom, and the divalent metal cation is coordinated by the N1 nitrogen atom.

14. A method for making conductive metal-containing nucleic acid duplexes comprising:

- providing a nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, the first and the second nucleic acid strands comprising a plurality of nitrogen-containing aromatic bases covalently linked by a backbone, the nitrogen-containing aromatic bases of the first nucleic acid strand being joined by hydrogen bonding to the nitrogen-containing aromatic bases of the second nucleic acid strand, the nitrogen-containing aromatic bases on the first and the second nucleic acid strands forming hydrogen-bonded base pairs in stacked arrangement along the length of the nucleic acid duplex;
- subjecting the nucleic acid duplex to a basic solution in the presence of a divalent metal cation under conditions effective to form a conductive metal-containing nucleic acid duplex, wherein the hydrogen-bonded base pairs of the conductive metal-containing nucleic acid duplex comprise an interchelated divalent metal cation coordinated to a nitrogen atom in one of the aromatic nitrogen-containing aromatic bases;
- providing an electron source electrically coupled to the conductive metal-containing nucleic acid duplex.

15. The method of claim 14 further comprising providing an electron sink electrically coupled to the conductive metal-containing nucleic acid duplex.

16. The method of claim 14 or 15 wherein the nucleic acid duplex is a deoxyribonucleic acid duplex comprising nitrogen-containing aromatic bases selected from the group consisting of adenine, thymine, guanine and cytosine.

17. The method of claim 14, 15 or 16 wherein the conditions effective to form a conductive metal-containing nucleic acid duplex are effective to substitute the

divalent metal cations for an imine proton of a nitrogen containing aromatic base in the nucleic acid duplex.

18. The method of any one of claims 14 through 17 wherein the divalent metal cation is selected from the group consisting of  $Zn^{2+}$ ,  $Co^{2+}$ , and  $Ni^{2+}$ .  
5
19. The method of any one of claims 14 through 18 wherein the basic solution is pH 8.5 or greater.
- 10 20. The method of any one of claims 14 through 19 wherein the electron source is an electron donor molecule capable of donating an electron to the conductive metal-containing nucleic acid duplex.
- 15 21. The method of any one of claims 15 through 20 wherein the electron sink is an electron acceptor molecule capable of accepting an electron from the conductive metal-containing nucleic acid duplex.
- 20 22. The method of claim 20 wherein the electron donor molecule is a fluorescent molecule.  
20
23. The method of claim 21 wherein the electron acceptor molecule is a fluorescent molecule.
24. The method of claim 22 wherein the electron donor molecule is fluorescein.  
25
25. The method of claim 23 wherein the electron acceptor molecule is rhodamine.
26. A method for detecting the formation of conductive metal-containing nucleic acid duplexes comprising:

- a) providing a first strand of nucleic acid;
- b) providing a second strand of nucleic acid;
- c) mixing the first strand of nucleic acid with the second strand of nucleic acid under conditions which allow complementary nucleic acid strands to hybridize;
- d) subjecting the mixed first and second nucleic acid strands to a basic solution in the presence of a divalent metal cation under conditions suitable for forming a conductive metal-containing nucleic acid duplex if the first and second nucleic acid strands are complementary;
- e) providing an electron source electrically coupled to the conductive metal-containing nucleic acid duplex;
- f) assaying for conductance of electrons from the electron source.

27. The method of claim 26 further comprising providing an electron sink electrically coupled to the conductive metal-containing nucleic acid duplex.

28. The method of claim 26 or 27 wherein the first and the second nucleic acid strands are deoxyribonucleic acid comprising nitrogen-containing aromatic bases selected from the group consisting of adenine, thymine, guanine and cytosine.

29. The method of claim 26, 27 or 28 wherein the divalent metal cation is selected from the group consisting of  $Zn^{2+}$ ,  $Co^{2+}$ , and  $Ni^{2+}$ .

30. The method of any one of claims 26 through 29 wherein the basic solution is pH 8.5 or greater.

31. The method of any one of claims 26 through 30 wherein the electron source is an electron donor molecule capable of donating an electron to the conductive metal-containing nucleic acid duplex.

32. The method of any one of claims 27 through 31 wherein the electron sink is an electron acceptor molecule capable of accepting an electron from the conductive metal-containing nucleic acid duplex.

5

33. The method of claim 31 wherein the electron donor molecule is a fluorescent molecule.

10

34. The method of claim 32 wherein the electron acceptor molecule is a fluorescent molecule.

35. The method of claim 33 wherein the electron donor molecule is fluorescein.

36. The method of claim 34 wherein the electron acceptor molecule is rhodamine.

15

37. The method of any one of claims 26 through 36 wherein the conditions suitable for forming a conductive metal-containing nucleic acid duplex are effective to substitute the divalent metal cations for an imine proton of a nitrogen containing aromatic base in the nucleic acid duplex.

20

38. The method of any one of claims 27 through 37 wherein the electron source is electrically coupled to the conductive metal-containing nucleic acid duplex by covalent attachment to the first strand of nucleic acid and the electron sink is electrically coupled to the conductive metal-containing nucleic acid duplex by covalent attachment to the second strand of nucleic acid.

25

39. A conductive metal-containing nucleic acid duplex produced by the process of any one of claims 14 through 25.

40. The use of a conductive metal-containing nucleic acid duplex to carry electrons, the conductive metal-containing nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, the first and the second nucleic acid strands comprising a plurality of nitrogen-containing aromatic bases covalently linked by a backbone, the nitrogen-containing aromatic bases of the first nucleic acid strand being joined by hydrogen bonding to the nitrogen-containing aromatic bases of the second nucleic acid strand, the nitrogen-containing aromatic bases on the first and the second nucleic acid strands forming hydrogen-bonded base pairs in stacked arrangement along the length of the conductive metal-containing nucleic acid duplex, the hydrogen-bonded base pairs comprising an interchelated divalent metal cation coordinated to a nitrogen atom in one of the aromatic nitrogen-containing aromatic bases.

10

41. The use of a conductive metal-containing nucleic acid according to claim 40, wherein the conductive metal-containing nucleic acid comprises deoxyribonucleic acid.

15

42. The use of a conductive metal-containing nucleic acid according to claim 40 or 41 wherein the nitrogen-containing aromatic bases are selected from the group consisting of adenine, thymine, guanine and cytosine.

20

43. The use of a conductive metal-containing nucleic acid according to any one of claims 40 through 42 wherein the divalent metal cation is selected from the group consisting of  $Zn^{2+}$ ,  $Co^{2+}$ , and  $Ni^{2+}$ .

25

44. The use of a conductive metal-containing nucleic acid according to any one of claims 40 through 43 wherein the conductive metal-containing nucleic acid further comprises an electron source electrically coupled to the conductive metal-containing nucleic acid duplex.

45. The use of a conductive metal-containing nucleic acid according to any one of claims 40 through 44 wherein the conductive metal-containing nucleic acid further comprises an electron sink electrically coupled to the conductive metal-containing nucleic acid duplex.

5

46. The use of a conductive metal-containing nucleic acid according to claim 44 wherein the electron source is an electron donor molecule capable of donating an electron to the conductive metal-containing nucleic acid duplex.

10 47. The use of a conductive metal-containing nucleic acid according to claim 45 wherein the electron sink is an electron acceptor molecule capable of accepting an electron from the conductive metal-containing nucleic acid duplex.

15 48. The use of a conductive metal-containing nucleic acid according to claim 46 wherein the electron donor molecule is a fluorescent molecule.

49. The use of a conductive metal-containing nucleic acid according to claim 47 wherein the electron acceptor molecule is a fluorescent molecule.

20 50. The use of a conductive metal-containing nucleic acid according to claim 48 wherein the electron donor molecule is fluorescein.

51. The use of a conductive metal-containing nucleic acid according to claim 49 wherein the electron acceptor molecule is rhodamine.

25

52. The use of a conductive metal-containing nucleic acid according to any one of claims 40 through 51 wherein the divalent metal cations are substituted for imine protons of the nitrogen-containing aromatic bases.

53. The use of a conductive metal-containing nucleic acid according to any one of claims 40 through 51 wherein at least one of the aromatic nitrogen-containing aromatic bases is thymine, having an N3 nitrogen atom, and the divalent metal cation is coordinated by the N3 nitrogen atom.

5

54. The use of a conductive metal-containing nucleic acid according to any one of claims 40 through 51 wherein at least one of the aromatic nitrogen-containing aromatic bases is guanine, having an N1 nitrogen atom, and the divalent metal cation is coordinated by the N1 nitrogen atom.

10

55. The use of a conductive metal-containing nucleic acid duplex to raise antibodies in an animal, the conductive metal-containing nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, the first and the second nucleic acid strands comprising a plurality of nitrogen-containing aromatic bases covalently linked by a backbone, the nitrogen-containing aromatic bases of the first nucleic acid strand being joined by hydrogen bonding to the nitrogen-containing aromatic bases of the second nucleic acid strand, the nitrogen-containing aromatic bases on the first and the second nucleic acid strands forming hydrogen-bonded base pairs in stacked arrangement along the length of the conductive metal-containing nucleic acid duplex, the hydrogen-bonded base pairs comprising an interchelated divalent metal cation coordinated to a nitrogen atom in one of the aromatic nitrogen-containing aromatic bases.

15

56. Antibodies to a conductive metal-containing nucleic acid duplex, the conductive metal-containing nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, the first and the second nucleic acid strands comprising a plurality of nitrogen-containing aromatic bases covalently linked by a backbone, the nitrogen-containing aromatic bases of the first nucleic acid strand being joined by hydrogen bonding to the nitrogen-containing aromatic bases of the second nucleic

20


25

acid strand, the nitrogen-containing aromatic bases on the first and the second nucleic acid strands forming hydrogen-bonded base pairs in stacked arrangement along the length of the conductive metal-containing nucleic acid duplex, the hydrogen-bonded base pairs comprising an interchelated divalent metal cation coordinated to a nitrogen atom in one of the aromatic nitrogen-containing aromatic bases.

5        57. A method for detecting amplification of a nucleic acid region comprising:

- a) providing a first amplification primer hybridizable to a first end of the nucleic acid region;
- b) providing a second amplification primer hybridizable to a second end of the nucleic acid region;
- c) providing conditions for amplification by polymerase chain reaction of the nucleic acid region between the first and second amplification primers to amplify the nucleic acid region;
- d) subjecting the amplified nucleic acid region to a basic solution in the presence of a divalent metal cation under conditions suitable for forming a conductive metal-containing nucleic acid duplex;
- e) providing an electron source electrically coupled to the conductive metal-containing nucleic acid duplex;
- f) assaying for conductance of electrons from the electron source.

10        58. The method for detecting amplification of a nucleic acid region further comprising the step of testing the nucleic acid region for susceptibility to a restriction endonuclease by subjecting the amplified nucleic acid to conditions suitable for digestion of the nucleic acid region by the restriction endonuclease if the nucleic acid region includes 15 a site recognized by the restriction endonuclease.

**Figure 1**





Figure 2






Figure 4

## Figure 5






Fig. 6



**Fig. 7**

<110> Lee, Jeremy S.

Aich, Palok

<120> CONDUCTIVE METAL-CONTAINING NUCLEIC ACIDS

<130> 81527-4

<150> CA 2,218,443

CA 2,229,386

<151> 1997-12-16

1998-02-11

<160> 4

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> sequence source :/note="Synthetic Sequence"

<400> 1

gtcacgatgg cccagtagtt 20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> sequence source :/note="Synthetic Sequence"

<400> 2

aactacttgg ccatcgtgac 20

<210> 3

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> sequence source :/note="Synthetic Sequence"  
<400> 3  
gctatgatcc aaaggccggc cccttacgtc agaggcgagc ctccaggtcc agct 54  
<210> 4  
<211> 54  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> sequence source :/note="Synthetic Sequence"  
<400> 4  
agctggacct ggaggctcgc ctctgacgta aggggccggc ctttgatca tagc 54

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 98/01149

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C07H21/00 C12Q1/68 C07K16/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07H C12Q C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 46568 A (CALIFORNIA INST OF TECHN) 11 December 1997  see the whole document ---	1,14,26, 39,40, 57,58
A	WO 96 40712 A (CALIFORNIA INST OF TECHN) 19 December 1996 cited in the application see claims 1-27; figures 1-5 ---	1,14,26, 39,40, 57,58
A	WO 95 15971 A (CALIFORNIA INST OF TECHN) 15 June 1995 cited in the application see claims 1-20; figures 1-4B ---	1,14,26, 39,40, 57,58

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

22 April 1999

07/05/1999

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Scott, J

## INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/CA 98/01149

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MURPHY C J ET AL: "LONG-RANGE PHOTOINDUCED ELECTRON TRANSFER THROUGH A DNA HELIX" SCIENCE, vol. 262, 12 November 1993, pages 1025-1029, XP002041920 cited in the application see abstract ---	1, 14, 26, 39, 40, 57, 58
A	CHEMICAL ABSTRACTS, vol. 91, no. 23, 3 December 1979 Columbus, Ohio, US; abstract no. 188121w, J.BANDEKAR ET AL.: "Copper (II)-Nucleic Acid Interactions - a Conformational Study." page 190; column 1; XP002100894 see abstract & J. THEOR. BIOL., vol. 79, no. 4, 1979, pages 443-454, ---	1, 39
A	CHEMICAL ABSTRACTS, vol. 92, no. 7, 18 February 1980 Columbus, Ohio, US; abstract no. 53563s, K.MASKOS ET AL.: "Interaction of Metal Ions with Nucleic Acids. Interaction of Copper (II) with Pyrimidine Nucleosides and their Derivatives." page 218; column 2; XP002100895 see abstract & ACTA BIOCHIM. POL., vol. 26, no. 3, 1979, pages 249-266, ----	1, 39

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No  
PCT/CA 98/01149

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9746568	A 11-12-1997	AU 3301497 A			05-01-1998
		CA 2257534 A			11-12-1997
WO 9640712	A 19-12-1996	US 5824473 A			20-10-1998
		AU 6166296 A			30-12-1996
		EP 0871642 A			21-10-1998
		US 5770369 A			23-06-1998
WO 9515971	A 15-06-1995	US 5591578 A			07-01-1997
		AU 703329 B			25-03-1999
		AU 1215295 A			27-06-1995
		CA 2178618 A			15-06-1995
		EP 0733058 A			25-09-1996
		JP 9506510 T			30-06-1997
		US 5824473 A			20-10-1998
		US 5770369 A			23-06-1998
		US 5780234 A			14-07-1998
		US 5705348 A			06-01-1998

THIS PAGE BLANK (USPTO)